Alba Ribera

Alba Ribera

Auto-generated profile, based on publicly available information

Alba Ribera

Department of Internal Medicine, Hospital de Barcelona, 08034 Barcelona, Spain

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Natividad BenitoNatividad Benito
Natividad Benito
IMIsabel Mur
Isabel Mur
ARAlba Ribera
Alba Ribera
ASAlex Soriano
Alex Soriano
Dolors Rodriguez-PardoDolors Rodriguez-Pardo
Dolors Rodriguez-Pardo
OMon behalf of the REIPI (Spanish Network for Research in Infectious Disease) Group for the Study of Prosthetic Joint Infections/GEIO (Group for the Study of Osteoarticular Infections), SEIMC (Spanish Society of Infectious Diseases and Clinical Microbiolo
on behalf of the REIPI (Spanish Network for Research in Infectious Disease) Group for the Study of Prosthetic Joint Infections/GEIO (Group for the Study of Osteoarticular Infections), SEIMC (Spanish Society of Infectious Diseases and Clinical Microbiolo
The aim of our study was to characterize the etiology of prosthetic joint infections (PJIs)—including multidrug-resistant organisms (MDRO)—by category of infection. A multicenter study of 2544 patients with PJIs was performed. We analyzed the causative microorganisms according to the Tsukayama’s scheme (early postoperative, late chronic, and acute hematogenous infections (EPI, LCI, AHI) and “positive intraoperative cultures” (PIC)). Non-hematogenous PJIs were also evaluated according to time since surgery: 12 months. AHIs were mostly caused by Staphylococcus aureus (39.2%) and streptococci (30.2%). EPIs were characterized by a preponderance of virulent microorganisms (S. aureus, Gram-negative bacilli (GNB), enterococci), MDROs (24%) and polymicrobial infections (27.4%). Conversely, coagulase-negative staphylococci (CoNS) and Cutibacterium species were predominant in LCIs (54.5% and 6.1%, respectively) and PICs (57.1% and 15.1%). The percentage of MDROs isolated in EPIs was more than three times the percentage isolated in LCIs (7.8%) and more than twice the proportion found in AHI (10.9%). There was a significant decreasing linear trend over the four time intervals post-surgery for virulent microorganisms, MDROs, and polymicrobial infections, and a rising trend for CoNS, streptococci and Cutibacterium spp. The observed differences have important implications for the empirical antimicrobial treatment of PJIs.

1 September 2014 in Journal of Infection
Verified
Journal Article
Closed access
ARA. Ribera
A. Ribera
LML. Morata
L. Morata
JMJ. Moranas
J. Moranas
JAJ.L. Agulló
J.L. Agulló
JMJ.C. Martínez
J.C. Martínez
Óscar MurilloÓscar Murillo
Óscar Murillo

28 September 2015 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
PDF file
ARAlba Ribera
Alba Ribera
EBEva Benavent
Eva Benavent
JLJaime Lora-Tamayo
Jaime Lora-Tamayo
FTFe Tubau
Fe Tubau
SPSalvador Pedrero
Salvador Pedrero
Óscar MurilloÓscar Murillo
Óscar Murillo
In the era of emergence of MDR Pseudomonas aeruginosa, osteoarticular infections (OIs) add more difficulties to its treatment. The role of β-lactams (BLs) is questioned and older drugs need to be reconsidered. The objective of this study was to describe our experience in the management of OIs caused by MDR P. aeruginosa and evaluate different therapeutic options. This was a retrospective analysis of a prospectively collected cohort (2004–13) of patients with OI caused by MDR P. aeruginosa. We created two groups: (i) Group A (more difficult to treat), prosthetic joint infections (PJIs) and osteoarthritis (OA) managed with device retention; and (ii) Group B (less difficult to treat), OA managed without device retention. Antibiotic treatment was administered according to clinician criteria: monotherapy/combined therapy; and BL used by intermittent bolus (IB)/continuous infusion. Of 34 patients, 15 (44.1%) had PJI and 19 (55.9%) had OA (8 related to an orthopaedic device). Twenty-three cases (68%) were caused by XDR P. aeruginosa. The initial management included removal of an orthopaedic device in 14 cases, together with antibiotic [alone, 19 (55.9%; 4 colistin, 14 BL-IB and 1 BL continuous infusion); and in combination, 15 (44.1%; 5 BL-IB and 10 BL continuous infusion)]. The overall cure rate was 50% (39% and 63% in Groups A and B, respectively), ranging from 31.6% with monotherapy to 73.3% with combined therapy (P = 0.016), with special interest within Group A (cure rate with combined therapy 71.4%, P = 0.049). After rescue therapy, which included removal of remaining devices, the cure rate reached 85.3%. We suggest that the BL/colistin combination is an optimized therapy for OI caused by MDR P. aeruginosa, together with an appropriate surgical treatment.

6 June 2015 in Infection
Verified
Journal Article
Closed access
PDF file
ARAlba Ribera
Alba Ribera
MLMaria Labori
Maria Labori
JHJavier Hernández
Javier Hernández
JLJaime Lora-Tamayo
Jaime Lora-Tamayo
LGLluís González-Cañas
Lluís González-Cañas
Óscar MurilloÓscar Murillo
Óscar Murillo

5 December 2024 in Microorganisms
Verified
Journal Article
Open access
PDF file
JGJavier García-González
Javier García-González
MCMaría Alexandra Cañas
María Alexandra Cañas
Guillermo CuervoGuillermo Cuervo
Guillermo Cuervo
MHMarta Hernández-Meneses
Marta Hernández-Meneses
MVMiguel Ángel Verdejo
Miguel Ángel Verdejo
TGthe Hospital Clínic Endocarditis Study Group
the Hospital Clínic Endocarditis Study Group
(1) Background: Alternative antibiotics are needed to treat infective endocarditis (IE) caused by non-faecalis/non-faecium enterococci; we aimed to assess the in vitro activity of ampicillin plus ceftriaxone (AMP + CTR) against these enterococci and to describe its clinical efficacy in IE cases. (2) Methods: Time–kill curves with standard (ISI) and high (IHI) inocula were performed to test VanC isolates [3 E. casseliflavus (ECAS) and 1 E. gallinarum (EGALL)] and non-VanC isolates [1 E. durans (EDUR), 1 E. hirae (EHIR) and 1 E. raffinosus (ERAF)]. The narrative literature review of IE cases treated with AMP + CTR was analyzed alongside three study cases. Clinical outcomes were relapse and death. (3) Results: Ampicillin plus gentamicin (AMP + GEN) showed synergistic and bactericidal activity against most isolates. AMP + CTR was synergistic at ISI for EGALL, EDUR, and EHIR and bactericidal against EHIR. At IHI, indifferent activity was observed for all isolates. In IE cases treated with AMP + CTR, it was only effective for EDUR and EHIR. Clinical information for EGALL IE is lacking. For IE caused by ECAS and ERAF, AMP + CTR seems suboptimal or ineffective, respectively. (4) AMP + CTR cannot be recommended for treating IE due to ECAS/ERAF. In contrast, this combination was effective in IE caused by EDUR/EHIR and could be recommended.

18 April 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
YMYolanda Meije
Yolanda Meije
CPCarles Pigrau
Carles Pigrau
NFNúria Fernández-Hidalgo
Núria Fernández-Hidalgo
MCMercedes Clemente
Mercedes Clemente
LOLucia Ortega
Lucia Ortega
JMJoaquín Martínez-Montauti
Joaquín Martínez-Montauti
Introduction: Carbapenems are considered the treatment of choice for extended-spectrum β–lactamase (ESBL) or Amp-C β–lactamase-producing Enterobacteriaceae bacteremia. Data on the effectiveness of non-intravenous carbapenem-sparing antibiotic options are limited. Objective: To compare the 30 day-mortality and clinical failures associated with the use of carbapenems vs an alternative non-intravenous antibiotic for the definitive treatment of ESBL/Amp-C positive Enterobacteriaceae bacteremia. Methods: This is a 12-year retrospective study (2004 - 2015) including all patients with bacteremia due to ESBL/Amp-C-producing Enterobacteriaceae. Given the lack of randomization of the initial therapies, a propensity score for receiving carbapenems was calculated. Results: There were 1115 patients with a first episode of bacteremia due to E. coli or K. pneumoniae, of which 123 were ESBL/Amp C-positive (11%). There were 101 eligible patients: 59 in the carbapenem group and 42 in the alternative treatment group (cotrimoxazole 59.5%, quinolones 21.4%). The most frequent sources of infection were urinary (63%) and biliary (15%). Compared to the carbapenem group, patients treated with the alternative regimen had a shorter hospital stay (median [IQR]: 7 days [5-10] vs 12 days [9-18], p<0,001). The use of an alternative non-IV treatment did not increase mortality (OR 0.27; 95% CI 0.05-1.61; p=.15). After controlling for confounding factors with the propensity score, the adjusted OR of carbapenem treatment was 4.95; 95% CI (0.94-26.01, p=.059). Conclusion: Alternative non-IV carbapenem-sparing antibiotics could have a role in the definitive treatment of ESBL/Amp-C-positive Enterobacteriaceae bloodstream infections, allowing a reduction in carbapenem use. The use of cotrimoxazole in this setting has shown favourable results.